COVID-19 (coronavirus) Statement


By August 28, 2023Specials

What’s New

The US Food and Drug Administration (FDA) has approved SkinVive by Juvéderm, the first hyaluronic acid intradermal microdroplet injection, for improving skin smoothness in adult patients ages 21 and older.

 SkinVive is the first and only treatment of its kind. The injectable gel works to improve skin quality in patients’ cheeks through increasing hydration and smoothing the skin.

SkinVive is comprised of hyaluronic acid, a naturally occurring substance in the body that binds water molecules to keep the skin plump and hydrated. With an injection of the hyaluronic acid-based gel, Juvéderm SkinVive treatment hydrates the skin, increasing skin smoothness. When hyaluronic acid is injected into the treatment area, it also increases collagen production, which improves skin elasticity and can help to reduce the appearance of fine lines. The result is healthy glowing and radiant skin.

Patients can immediately return to their regularly scheduled activities without downtime. Most patients experience mild side effects, such as swelling and discoloration at the injection site, which should resolve on their own within 30 days.

SkinVive is a skin hydrating treatment and results are long-lasting and become apparent after only one treatment session, meaning no additional treatment sessions are necessary until the effects begin to wear off. According to the clinical trials, most patients still noted the revitalizing effects of the treatment six months after receiving the injections.

Treatments with SkinVive will be available this month September 18, 2023